Emergency contraception (EC) is a method to be used in the case of unprotected sexual intercourse, failure of a regular contraceptive method, or after rape to try to prevent an unintended pregnancy. Oral EC remains surrounded by controversy, much due to myths and misconceptions among the public, policy makers and healthcare providers. This has resulted in restrictions on its availability in many parts of the world and restrictions on women's access to it. The aim of this article is to provide an evidence-based view on some of these common controversial issues surrounding oral EC in clinical practice.
Introduction
Emergency contraception (EC) can be provided as either an oral hormonal method or the copper intrauterine contraceptive device (Cu-IUD). The Cu-IUD is the most effective EC with failure rates of <0.1%. 1, 2 In contrast to oral methods, the Cu-IUD has both pre-and post-fertilisation effects, 3 can be used over a wider time period than oral EC and can be retained for highly effective ongoing contraception (Table 1) . However, the Cu-IUD may not be the preferred or suitable method for all users and is also more provider-dependent. Hence oral EC remains the more commonly used approach.
The first oral EC introduced in the 1960s consisting of high oral doses of estrogens was phased out due to a high incidence of estrogen-related adverse effects. In 1974, a combination of ethinylestradiol (100 lg) and DL-norgestrel (1 mg) administered within 72 hours of unprotected sexual intercourse (UPSI) with a repeat dose 12 hours after was introduced. 2 This 'Yuzpe' regimen was gradually replaced by levonorgestrel (LNG) in the 1990s, as fewer adverse effects and higher clinical efficacy with LNG were demonstrated. 4 A single dose of LNG (1.5 mg) administered within 72 hours of UPSI is the recommended regimen for LNG EC. 5 Although licensed for use within 72 hours, there is evidence that efficacy may be maintained up to 96 hours post UPSI. 6 In recent years, a single 30-mg oral dose of ulipristal acetate (UPA), a progesterone receptor modulator (PRM), has been introduced as EC. The UPA EC regimen is slightly more effective than LNG as shown by a meta-analysis (n = 3242) of two randomised controlled comparative trials. 7, 8 The efficacy of UPA EC is maintained up to 120 hours after UPSI, 8, 9 which is the recommended time limit in the product license.
Mifepristone is another PRM that was first studied as an EC in 1992 10, 11 at a dose of 600 mg taken within 72 hours of UPSI. Subsequently, equivalent effectiveness as EC was confirmed with lower doses at 10-50 mg. 12 According to the latest Cochrane review, mifepristone at mid-dose (25-50 mg) ranks top among the oral EC methods in terms of efficacy. 1 However, mifepristone preparations at an EC dose are available in only a few countries. 13 
Mechanisms of action of EC
What are the mechanisms of action of EC?
All oral methods of EC are capable of delaying ovulation. As spermatozoa survive in the female reproductive tract for up to 5 days, oral EC can prevent pregnancy if it can delay ovulation long enough for spermatozoa to have lost their fertilising capacity or are no longer viable. 5 The Yuzpe regimen is thought to act by inhibiting or delaying ovulation. 14, 15 Other postovulatory mechanisms of action have been proposed based on epidemiological modelling, 16 ,17 but such evidence was only circumstantial. Some minor morphological or molecular changes in the endometrium following administration of Yuzpe have been reported in some studies [18] [19] [20] but not others, 15 and the actual clinical significance of these alterations is uncertain. The high dose of progestogen in Yuzpe may also thicken the cervical mucus and impair sperm penetration, but this is probably not relevant in the context of EC, which is used some time after the UPSI. 21 There are no reported data on the direct effect of the Yuzpe regimen on sperm or fallopian tube function. Levonorgestrel EC acts by blocking the luteinising hormone (LH) surge and hence inhibiting follicular growth or delaying rupture. However, it is not effective if administered after the onset of the LH surge. [22] [23] [24] In vitro studies showed that LNG at concentrations relevant for EC had no significant effect on sperm function nor fertilisation, [25] [26] [27] nor on endometrial receptivity and embryo attachment. 28, 29 Although one in vitro study showed that it might inhibit muscular contractility of the fallopian tube, 30 other data suggested that LNG inhibited ciliary beat frequency and muscular contractility only at supra-pharmacological concentrations. 31 Overall, LNG probably has minimal postovulatory actions, if any, and this may explain the observation that LNG is only effective for EC if administered preovulation but not postovulation. 31, 32 Mifepristone at a dose of ≥10 mg delays follicular development and ovulation, although ovulation usually takes place eventually. 33, 34 A small pilot study showed that even when mifepristone at a dose of 200 mg was administered after the onset of the LH surge, ovulation was not consistently blocked. 35 In vitro studies suggested that mifepristone at the EC dose may inhibit endometrial receptivity 28, 29 and 28 but not sperm function or fertilisation. 26, 28, 29, 36 Ulipristal acetate exerts its EC action by blocking or delaying ovulation, and such an effect of UPA remains evident even when administered after the onset of the LH surge but before the peak. 37 Follicular rupture can be delayed by at least 5 days after intake of UPA in 100% of cases when given before the onset of LH surge and in 79% after the onset but before the LH peak. 38 This means that UPA has a wider window of action than LNG and remains effective in the immediate preovulatory phase when the risk of conception is greatest, hence explaining its higher efficacy compared with LNG in clinical trials. 8 Postovulatory administration of UPA at the EC dose may induce some immunohistochemical and molecular changes in the endometrium, 39 but other in vitro studies have shown that UPA at concentrations relevant for EC do not interfere with embryo attachment to the endometrium. 40, 41 UPA at pharmacological concentrations can suppress ciliary beating and muscular contractility in fallopian tube, 42 as well as modulate sperm function by inhibiting sperm hyperactivation, progesterone-induced acrosome reaction and calcium influx. 26 However, the clinical relevance of these in vitro findings remains uncertain. Sperm may only take minutes to reach the fallopian tube after UPSI, 23 and this window is too short for the sperm-targeted action in the EC context. Furthermore, a recent clinical study (n = 693) indicated that UPA had significantly higher efficacy as EC when administered before compared with after ovulation, 43 which implied that postovulatory mechanisms may not contribute much, if at all, to the action of UPA EC.
Does EC induce a miscarriage or an ectopic pregnancy?
In theory any postfertilisation mechanisms of action of oral EC, if they exist, would act before the establishment of pregnancy, i.e. before embryo implantation. Hence, EC is not an abortifacient. The rate of miscarriage in clinical trials of EC is no higher than what one might expect to observe in the general population. 8, 42 Although in vitro studies might suggest some action of EC on tubal function, a systematic review showed no higher incidence of ectopic pregnancy after oral EC than in the general population. 44 
Are mechanisms of action important to users?
Survey data from Europe and the USA show that up to 40% of women report not knowing how oral EC works. 45, 46 There are few data on whether EC users are concerned with how EC works. A survey of 500 women in the UK showed that most were hypothetically prepared to use an EC pill that might prevent or even disrupt implantation. 47 Clearly a method that worked by disrupting implantation may raise legal issues in many settings, but would be permissible in countries where 'menstrual induction' (i.e. evacuation of the uterus in women with delayed menses without laboratory confirmation of pregnancy) is permitted, such as China. 48 
Effectiveness of EC

How effective is EC?
There has never been a placebo-controlled trial of oral EC because of ethical concerns over those assigned to the placebo group, as EC is widely recognised to reduce unintended pregnancies. This is inferred in most comparative clinical trials where the pregnancy rates observed after EC use are lower than what might have occurred in the absence of EC (based upon data for the risk of conception on the respective cycle days). However, calculations of expected pregnancy rates falsely assume that we can accurately determine the phase in the menstrual cycle when intercourse took place, that women have had just one episode of UPSI and that sperm have entered the reproductive tract. In reality, this may not be the case. 5, 16, 17 In a randomised trial (n = 1899), UPA was estimated to have prevented 67% of expected pregnancies whereas LNG was estimated to have prevented 52%. 8 The reported pregnancy rates in the comparative clinical trials of UPA and LNG EC were around 1 and 3%, respectively, compared with the expected rate of 4% (in the absence of EC). 5, 8 Studies have also demonstrated lower pregnancy rates with earlier administration of EC after UPSI, which may be because the woman is less likely to have already ovulated. 5 
Does obesity impact on effectiveness of EC?
A secondary analysis of two randomised controlled trials comparing LNG and UPA EC demonstrated that obesity, i.e. body mass index (BMI) ≥ 30 kg/m 2 , increased the risk for pregnancy after EC, and the risk was more pronounced with LNG than UPA (four-fold versus two-fold). 49 The same trend was concluded in a pooled analysis of a phase III study of UPA. 50 However, the trials were not designed to address the issue of BMI on efficacy of EC. In addition, the numbers of women with obesity were low, as were the number of pregnancies in this group. Also, in many cases, height and weight had been self-reported. Furthermore, previous studies of LNG EC had failed to show an impact of BMI upon pregnancy rate. 51, 52 In 2014, the European Medicines Agency reviewed the available data and concluded that the data were not sufficiently robust to discourage women with obesity from using either UPA or LNG EC. 53 More recently, a pooled analysis of randomised controlled trials of LNG conducted by WHO (n = 6873) reported higher pregnancy rates among women with obesity compared with women of normal weight (although this was only statistically significant with regression analysis and adjustment for several factors). 54 There are also pharmacokinetic data indicating that LNG takes a longer time to achieve steady-state levels in women with obesity compared with those of normal BMI, which can be overcome by doubling the dose of LNG. 55 Conversely, the pharmacokinetics of UPA is not affected by obesity. 56 It is very unlikely that there will be a definitive randomised controlled trial comparing the efficacy of EC in women with obesity versus those with normal weight, so for now the uncertainty regarding the impact of BMI on the efficacy of EC remains. Nonetheless, the current UK guideline recommends that women weighing >70 kg or with BMI > 26 kg/m 2 should be offered UPA EC or consider a double dose (3 mg) of LNG EC, although it is not known which of these two options is more effective.
5
How good is advance provision of EC at preventing unintended pregnancy at population level?
Population studies and clinical trials of advance provision of EC (supply to keep at home in case of need) indicate that use of EC does not reduce rates of unintended pregnancy or termination of pregnancy (TOP) at population level. A Cochrane review of six randomised controlled trials of over 6300 women with advance supplies of EC compared with standard access failed to demonstrate any reduction in pregnancy rates at 3, 6 or 12 months. 57 This is probably because many women underestimate their risk of pregnancy and do not take EC after UPSI even if an advanced supply is provided. 58 
Safety of EC
Is EC generally safe to use?
In contrast to the Yuzpe regimen, adverse effects associated with use of LNG EC or UPA EC are infrequent, minor and generally well-tolerated. Serious adverse effects are very rare. 5, 8 The pattern of adverse effects (e.g. nausea, headache) reported after UPA is similar to that after LNG, 8 and is similar for adults and adolescents. 59 A review of the safety of UPA EC by the European Medicines Agency 53 concluded that UPA was so safe that a change in classification status from prescription to nonprescription was recommended and this has been widely adopted in most European countries. 13 Does EC exposure have a harmful effect on a pregnancy?
A prospective cohort study showed no association between the use of LNG EC and the risk of major congenital malformation, pregnancy complications or any other adverse pregnancy outcomes. 60, 61 Data regarding the effects of UPA on pregnancy outcome are inevitably limited due to the small number of pregnancies reported after UPA EC, and the fact that many of these unintended pregnancies were voluntarily terminated. However, the available data from over one million women who used UPA in the clinical trials and during postmarketing surveillance have been consistent with no increased risk of miscarriage, ectopic pregnancy or congenital abnormality in babies after UPA exposure. 42 Regarding the Yuzpe regimen, there is some reassurance extrapolating from a meta-analysis of 12 available prospective studies on around 6000 exposed women that did not find any statistically significant association between oral contraceptive use in early pregnancy and fetal malformation. 62 Indirect evidence from in vitro studies also showed that LNG or UPA at EC doses had no effect on human blastocyst viability 28, 29, 41 in spite of sufficient time being allowed for the embryo to undergo any degenerative changes that LNG or UPA could possibly cause within the culture system.
Does EC have an adverse effect on breastfeeding?
Emergency contraception is not required before 21 days postpartum. 63 Women who take LNG while breastfeeding can be advised that they can continue to breastfeed. 63, 64 A recent systematic review suggested no adverse effect on breastfeeding performance or infant outcomes with the use of progestogen-only contraception. 65 Guidelines therefore advise that women can continue to breastfeed after taking LNG for EC. [66] [67] [68] There are no data on effects of UPA on breastfeeding nor on infant outcomes. As UPA is lipophilic, secretion to breast milk could be expected. However, levels are likely to be extremely low and adverse effects are unlikely. The manufacturer advises women to discard breast milk for 7 days after UPA, which has been endorsed by UK and WHO guidelines. 5, 66, 67 In contrast, US guidelines advise discarding milk for 24 hours only. 68 Even this advice may be overly cautious as studies of another PRM (mifepristone) have shown that following 200 mg of mifepristone (which is four times the EC dose), the peak mifepristone levels in breast milk are extremely low (<1.5% of maternal levels). 69 
Does use of EC increase risky sexual behaviour?
There were reservations among users and healthcare providers against making oral EC available without prescription, mainly because of the myths that easier access to EC might compromise the use of regular contraception or promote risky and irresponsible sexual behaviours. 57 However, numerous studies showed no evidence that availability of EC resulted in women abandoning regular contraception in favour of EC. 57 In addition, advance provision of EC does not appear to increase the frequency of UPSI or sexually transmitted infections. 57 Is it safe to use oral EC more than once in the same cycle? Follicular development and ovulation are only postponed after intake of EC, so women are at risk of becoming pregnant if further acts of UPSI take place in the same cycle; 5 such risk has been reported as three-to four-fold compared with no further UPSI. 1, 49 Based on the half-life of LNG and UPA, repeat use of EC is recommended in the case of further UPSI beyond 24 hours from the last EC use. 66 A study of women taking pericoital LNG-EC repeatedly, i.e. as required either before or within 24 hours of UPSI as their main method of contraception, reported a pregnancy rate of 11 per 100 women-years. It was well tolerated with a low incidence of adverse effects, and with an efficacy that is better than no method. 70 Nevertheless, women should be informed that repeated EC use is less effective than a regular method of contraception and may result in irregular bleeding. 67 In a biomedical study where UPA at EC dose was administered every 5 or 7 days over a period of 8 weeks, ovulation was delayed but eventually happened in most women. 71 This was associated with irregular bleeding. Assessments of endometrium showed morphological changes associated with PRM exposure. Tests of liver function, haematinics and thrombotic markers were also normal. The European Medicines Agency reviewed the data and concluded that repeat administration of UPA in the same cycle was safe. 53 
Contraception after EC
Do women want to start effective contraception after EC?
It is important that EC users who will remain sexually active start an effective method of contraception as soon as possible. If women attend a family planning service or a general practitioner for EC, then they can be provided with ongoing contraception at this same visit. Studies from the UK suggest that up to 50% of women accessing EC from a family planning service are provided with a contraceptive method at this time, 72, 73 and a study from Sweden showed that over half of women receiving UPA were using effective contraception 6 months later. 74 Of course, women are increasingly choosing to access EC from the pharmacy (in countries where this is available without prescription), 13, 75 but most pharmacists cannot provide ongoing hormonal contraception without a prescription. In a survey of women attending UK pharmacies for EC, 64% indicated that they would value the opportunity to receive a supply of contraception from the pharmacy. 76 A pilot study showed that women provided with a 1-month supply of a progestogen-only pill along with EC from a pharmacy were more likely to be using effective contraception 2 months later than women attending pharmacies where they only received advice on where to obtain supplies of contraception (56% versus 16%). Larger robust studies are needed to determine if this strategy can increase the uptake of effective contraception after EC from the pharmacy. 77 Is it safe to 'quick start' hormonal contraception immediately after EC?
Guidelines advise that after LNG EC women can start hormonal contraception immediately, based on the assumption that LNG will not interact with hormonal contraception. 5 However, UPA is a PRM and so there is a theoretical concern about interaction with progestogen-containing hormonal contraception by competition at the progesterone receptor, as has been shown for other PRMs. 78 Two biomedical studies have addressed the impact of UPA on hormonal contraception in the presence of a dominant follicle. One showed no adverse impact of UPA on the ability of combined oral contraception initiated 1 day later to induce ovarian quiescence, but this study was not designed to examine any impact of combined oral contraception on the ability of UPA to delay ovulation. 79 The other 80 reported that UPA did not affect the contraceptive action of a desogestrel-only pill on cervical mucus or ovarian quiescence. However, an ovulation rate of 45% within 5 days was reported among women quick-started on the desogestrel-only pill after UPA, compared with 3% among women taking placebo pills. Hence, immediate start of a desogestrel-only pill appears to counteract the contraceptive effect of UPA and expose the individual to the same risk of pregnancy faced without use of EC. This was a small study of one type of hormonal contraception, but it is biologically plausible that this effect may apply more broadly. Hence, it is advisable to delay initiation of hormonal contraception for at least 5 days after UPA, 5 although some suggest that it may be more biologically correct to count the 5 days from the episode of UPSI (lifespan of spermatozoa) rather than from intake of UPA. 81 Although UK guidelines advise that the LNG-releasing intrauterine system should not be inserted until pregnancy has been excluded, there are some data to suggest that starting this method with LNG-EC may be a reasonable option for some women. 82 More research is required.
The future: can we develop a more effective EC?
Prostaglandins play a critical role in follicle rupture. Preliminary data suggest that addition of meloxicam (a cyclooxygenase inhibitor) to LNG may potentiate its effect in suppressing ovulation, 83 but whether the same applies to UPA is uncertain, and needs to be explored in large robust trials.
'Contragestion' was the term used by contraceptive researchers in the 1980s to describe a potential method that could remain effective after ovulation to prevent or disrupt the establishment of a very early pregnancy at the end of the luteal phase. 84, 85 This conveys the concept of an 'emergency' method that works throughout the cycle to prevent pregnancy. Mifepristone combined with misoprostol may potentially be developed for this purpose in countries where this is allowed. 86 
Conclusions
This article provides an evidence-based view on the current oral EC methods (summarised in Table 1 ). Myths and misconceptions surrounding oral EC have hampered availability, access to, and use of EC by women. The best evidence shows that oral EC works by delaying ovulation (if that has not already taken place), is not as effective as many might believe, is extremely safe and does not lead to women abandoning regular contraception or increased prevalence of sexually transmitted infections. So what has all the controversy been about?
All women deserve a second chance to prevent an unintended pregnancy and we need to develop strategies to maximise the effectiveness of EC. First, use of the Cu-IUD as the most effective EC should be considered. Furthermore, women should be advised to avoid further UPSI in the same cycle after oral EC, and should acquire an effective method of contraception as soon as possible.
More research is required to explore the provision of ongoing contraception with oral EC from the pharmacy, and also to investigate the possible impact of obesity on oral EC. Finally, women deserve a more effective oral EC, which can prevent pregnancy even after ovulation has occurred and which could potentially also be used 'on demand'. This could be an EC that prevents implantation, but could also be a contragestive pill that women could take as and when required and that works throughout the cycle, although this remains controversial.
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For emergency contraception, political gaps are not scientific gaps DK Turok Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA Emergency contraception (EC) is the only opportunity for women to prevent an unwanted pregnancy after unprotected intercourse. Simple compassion for women who are in this situation combined with solid scientific data to support the safety of oral EC should be enough to promote strategies to expand access to these medications as well as the most effective method of EC, the copper IUD. A wide array of women's healthcare organisations promote increasing EC access to improve clinical care, a position clearly supported by the four foundations of biomedical ethics: autonomy, nonmaleficence, beneficence, and justice. Ironically, in the political sphere, conservative morals are the foundation for limiting access, despite the conflict with scientific evidence. In this issue, Drs. Cameron, Li, and Gemzell-Danielson present an opportunity for clinicians to review the data behind public and scientific oral EC controversies.
These controversies can easily be divided into two groups. The first group contains issues that despite scientifically sound evidence remain controversial because of religious and political opposition. In essence, these issues are not scientifically controversial. Contention exists only because EC provides greater reproductive autonomy and thus clashes with conservative sexual values, which aim to shame women having sex for pleasure and not for procreation. Limiting effective methods of post coital contraception supports this position and limits women's sexual freedom. This scientifically uncontroversial group includes the oral EC mechanism of action, excellent safety, lack of population effect, and inability to serve as an abortifacient. The second group contains topics where scientific evidence is lacking or imperfect. This group includes the potential decrease in progestin containing contraception efficacy when initiated with ulipristal, methods to manage the potential negative effect of obesity on EC efficacy, and whether the oral EC mechanism of action is important to users. Ironically, despite sound evidence, it is this first group which forms the foundation for opposition to implementing EC best practices. As scientists and clinical researchers have done their work here, this realm is now the work of policy experts, advocates, and politicians.
There are many examples of politics influencing good clinical care, which for oral EC means improving access and affordability. Inexpensive over the counter (OTC) availability of oral EC is the target for advocates and politicians on both sides. Whereas oral levonorgestrel and ulipristal EC products are available OTC in Europe, a long political battle has been waged on this issue in the USA, where OTC ulipristal is not even on the horizon. However, promoting regulatory approval is not enough. Politics can also support pharmacists who refuse women access to EC or prevent this behaviour. Sexual assault victims are a critical group in need of EC and several entities have passed legislation mandating offering EC when these women present for medical care. Finally, EC coverage can be mandated or restricted through private and government-sponsored medical coverage. In the USA, a Supreme Court decision enables private companies to forego EC insurance coverage for employees based on moral beliefs even though the court has acknowledged these are not scientifically valid. In areas of medical controversy, scientific evidence and biomedical ethics can lead both clinicians and policy makers in the right direction. In this case the road clearly leads to increasing EC access and affordability.
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